¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antibody binding site"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • cross-reacting antibody
    ±³Â÷¹ÝÀÀÇ×ü
  • cytolytic antibody
    ¼¼Æ÷¿ëÇØÇ×ü
  • cytophilic antibody
    ¼¼Æ÷ģȭÇ×ü
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼ºÇ×ü
  • cytotropic antibody
    ¼¼Æ÷ģȭÇ×ü
  • cell-associated antibody
    ¼¼Æ÷¿¬°üÇ×ü
  • cell-bound antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • cell-fixed antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • cellular antibody
    ¼¼Æ÷Ç×ü
  • chimeric antibody
    Ű¸Þ¶óÇ×ü
  • diagnostic antibody
    Áø´Ü¿ëÇ×ü
  • direct fluorescent antibody staining
    Á÷Á¢Çü±¤Ç×ü¿°»ö(¹ý)
  • divalent antibody
    À̰¡Ç×ü
  • enzyme labeled antibody
    È¿¼ÒÇ¥ÁöÇ×ü
  • enzyme-antibody conjugate
    È¿¼ÒÇ×üÁ¢ÇÕü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • circulating antibody
    Ç÷ÁßÇ×ü
  • cold antibody
    Àú¿ÂÇ×ü
  • complement-fixing antibody
    µµ¿òü°áÇÕÇ×ü, º¸Ã¼°áÇÕÇ×ü
  • complete antibody
    ¿ÏÀüÇ×ü
  • coprecipitation antibody
    µ¿¹ÝħÀüÇ×ü
  • cross-reacting antibody
    ±³Â÷¹ÝÀÀÇ×ü
  • cytolytic antibody
    ¼¼Æ÷¿ëÇØÇ×ü
  • cytophilic antibody
    (¢¡cytotropic antibody) ¼¼Æ÷ģȭÇ×ü
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼ºÇ×ü
  • cytotropic antibody
    ¼¼Æ÷ģȭÇ×ü
  • diagnostic antibody
    Áø´Ü¿ëÇ×ü
  • divalent antibody
    À̰¡Ç×ü
  • enzyme labeled antibody
    È¿¼ÒÇ¥ÁöÇ×ü
  • fluorescent antibody
    Çü±¤Ç×ü
  • heat labile antibody
    ¿­¹Î°¨Ç×ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • antibody half-life
    Ç×ü¹Ý°¨±â(ù÷ô÷ÚâÊïÑ¢).
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody production
    Ç×ü»ý»ê(¡­ßæß§).
  • antibody removal
    Ç×üÁ¦°Å
  • antibody response
    Ç×ü¹ÝÀÀ(¡­Úãëë).
  • antibody screening cells
    Ç×ü¼±º°Ç÷±¸
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • antibody structure
    Ç×ü±¸Á¶(¡­Ï°ðã).
  • antibody synthesis =a. production
    Ç×ü»ý»ê, Ç×üÇÕ¼º.
  • antibody titer
    Ç×ü°¡(ù÷ô÷ʤ).
  • antibody to HBc ag
    B Çü °£¿°ÇÙ½ÉÇ׿ø¿¡´ëÇÑ Ç×ü
  • antibody to HBe ag
    B Çü °£¿°¿ÜÇÇÇ׿ø¿¡´ëÇÑ Ç×ü
  • antibody to HBs ag
    B Çü °£¿°Ç¥¸éÇ׿ø¿¡´ëÇÑ Ç×ü
  • antibody to HD ag
    HD Ç׿ø¿¡´ëÇÑ Ç×ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • unsaturated vitamin B12 binding capacity
    ºÒÆ÷È­ºñŸ¹Î B12 °áÇÕ´É
  • acetylcholine receptor antibody
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëüÇ×ü
  • acetylcholine receptor antibody assay
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü Ç×Ã¼ÃøÁ¤
  • adcc(antibody dependent cell mediated cytotoxicity)
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º(ù÷ô÷ëîðíá¬øàØÚË¿á¬øàÔ¸àõ)
  • albumin agglutinating antibody
    ¾ËºÎ¹ÎÀÀÁýÇ×ü(¡­ëêó¢ù÷ô÷).
  • anaphylactic antibody
    ¾Æ³ªÇʶô½Ã¼º Ç×ü(¡­ù÷ô÷).
  • anaphylactic antibody
    ¾Æ³ªÇʶô½Ã½º [À¯¹ß]Ç×ü
  • anti-La antibody
    Ç×LaÇ×ü
  • anti-RNP antibody
    Ç× RNPÇ×ü
  • anti-Ro antibody
    Ç× RoÇ×ü
  • anti-SM antibody
    Ç×SMÇ×ü
  • anti-cardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • anti-sm antibody
    Ç×Sm Ç×ü(ù÷¡­ù÷ô÷)
  • antibody
    Ç×ü(ù÷ô÷)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • interacting site
    »óÈ£ÀÛ¿ë(ßÓû»íÂéÄ) ÀÚ¸®
  • internal resolution site
    ³»°áÁ¤(Ү̿ïÜ) ÀÚ¸®
  • mutable site
    °¡º¯ÀÌ(ʦܨì¶)ÀÚ¸®
  • Ori site
    Ori ÀÚ¸®
  • peptidyl site
    ÆéŸÀ̵å ÀÚ¸®
  • peptidyl-tRNA site
    ÆéŸÀ̵å-tRNA ÀÚ¸®
  • polycloning site
    ´Ù(Òý)Ŭ·Î´× ÀÚ¸®
  • privileged site
    ƯÀü(÷åîð)ÀÚ¸®
  • prophage attachment site
    ÇÁ·ÎÆäÀÌÁö ºÎÂø(Üõó·)ÀÚ¸®
  • P site
    P ÀÚ¸®
  • recognition site
    ÀνÄ(ìããÛ)ÀÚ¸®
  • regulatory site
    Á¶Àý(ðàï½) ÀÚ¸®
  • replacement site
    ´ëÄ¡ ÀÚ¸®
  • restriction site
    Á¦ÇÑ ÀÚ¸®
  • R site
    R ÀÚ¸®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
CMS children's medical services; Christian Medical Society; chronic myelodysplastic syndrome; chromosome...
E* lesion on the erythrocyte cell membrane at the site of complement fixation
FMR fragile site mental retardation [syndrome]; Friend-Moloney-Rauscher [antigen]
fra fragil [site]
FRAXE X-linked mental retardation-fragile site [syndrome]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
ARS antigen recognition site
cos cohesive end site
DIS dimerization initiation site
ES expression site
IRES internal ribosomal entry site
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • humoral cytotoxic antibody
    ü¾×¼º ¼¼Æ÷ µ¶¼º Ç×ü
  • immunofluorecent antibody test
    ¸é¿ª Çü±¤ Ç×ü °Ë»ç¹ý
  • intrinsic factor antibody
    ³»Àμº ÀÎÀÚ Ç×ü
  • Jo-1 antibody
    Jo-1 Ç×ü
  • labelled antibody
    Ç¥Áö Ç×ü
    ±× ¿òÁ÷ÀÓÀ̳ª À§Ä¡¸¦ ¾Ë±â À§ÇØ ¶óº§¸µÇÑ Ç×ü.
  • leukocyte antibody
    ¹éÇ÷±¸ Ç×ü
  • monovalent antibody
    Àϰ¡ Ç×ü
  • multivalent antibody
    ´Ù°¡ Ç×ü
  • panel in antibody identification
    Ç×ü µ¿Á¤ ÆÐ³Î, Ç×ü µ¿Á¤¿ë ÆÐ³Î
    Ç×üÀÇ »ý¼º ¿©ºÎ¸¦ ¾Ë¾Æº¸±â À§ÇÑ ÆÐ³ÎÆÇ.
  • percent reactive antibody test
    ÆÛ¼¾Æ® ¹ÝÀÀ Ç×ü °Ë»ç
  • polyclonal antibody
    ´ÙŬ·Ð¼º Ç×ü
  • reagin antibody
    ¸®¾ÆÁø Ç×ü
  • salivary antibody
    Ÿ¾× Ç×ü
  • sensitizing antibody
    °¨ÀÛ Ç×ü
  • univalent antibody
    Àϰ¡ Ç×ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
GTP-binding protein <molecular biology, protein> There are two main classes of G-proteins, the heterotrimeric G proteins that associate with receptors of the seven transmembrane domain superfamily and are involved in signal transduction and the small cytoplasmic G-proteins.
Regulatory proteins found in all cells. They are versatile molecular switches, involved in the control of a wide range of biological processes - protein synthesis, signal transduction pathways, growth and differentiation. They all act through a common molecular mechanism based on their ability to bind the guanine nucleotides GTP and GDP selectively and with high affinity.
Stimulatory G-proteins are permanently activated by cholera toxin, inhibitory ones by pertussis toxin. Transducin was one of the first of the heterotrimeric G-proteins to be identified.
The small G-proteins are a diverse group of monomeric GTPases that include ras, rab, rac and rho and that play an important part in regulating many intracellular processes including cytoskeletal organisation and secretion. Their GTPase activity is regulated by activators (GAPs) and inhibitors (GIPs) that determine the duration of the active state.
(12 Jul 2000)
RNA-binding proteins Proteins which bind to RNA molecules. Certain structure motifs are common to several of the proteins, such as arginine (arg)-rich tracts, typically consisting of alternating arg-asp, arg-ser, or arg-gly residues. These proteins also tend to have a common ribonucleotide sequence domain.
(12 Dec 1998)
guanosine triphosphate binding protein <protein> A type of protein embedded in the cytoplasmic membrane of the cell which transmits signals from outside the cell (such as from hormones binding to receptors on the outside of the cell) to the inside of the cell, where it causes some sort of biochemical reaction within the cell to the signal (such as the altering of metabolic pathways or gene expression). The process by which the protein does this is unclear but involves exchanging a molecule of GDP for a molecule of GTP.
(09 Oct 1997)
placental calcium-binding protein <protein> Calcium binding protein of placenta, uterus and vasculature containing the EF hand motif.
(18 Nov 1997)
competitive binding assay General term for an assay in which a binder competes for labelled versus unlabelled ligand; following separation of free and bound ligand, the ligand (the analyte assayed) is quantitated by relating bound and unbound ratios to known standards.
See: enzyme-linked immunosorbent assay, radioreceptor assay, immunoassay, enzyme-multiplied immunoassay technique, radioimmunoassay.
Synonym: displacement analysis, saturation analysis.
(05 Mar 2000)
complement binding assay A test for the detection of immune complexes.
(05 Mar 2000)
corticosteroid-binding globulin <chemical> Chemical name: Transcortins
(12 Dec 1998)
corticosteroid-binding protein <chemical> Chemical name: Transcortins
(12 Dec 1998)
progesterone-binding globulin A glycoprotein migrating as alpha 1-globulin, molecular weight 70,000 to 120,000. The protein, which is present in increased amounts in the plasma during pregnancy, binds mainly progesterone, with other steroids including testosterone competing weakly.
(12 Dec 1998)
heparin binding growth factor <growth factor> Acidic fibroblast growth factor (alpha FGF, HBGF 1) and basic FGF (beta FGF, HBGF 2) are the two founder members of a family of structurally related growth factors for mesodermal or neuroectodermal cells.
Synonym: heparin binding growth factor.
Acronym: FGF
(18 Nov 1997)
protein binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
(12 Dec 1998)
serotonin-binding protein kinase <enzyme> An aspect of protein kinases EC 2.7.1.37
Registry number: EC 2.7.1.-
Synonym: sbp kinase
(26 Jun 1999)
sex hormone-binding globulin A glycoprotein migrating as a beta-globulin. Its molecular weight, 52,000 or 95,000-115,000, indicates that it exists as a dimer. The protein binds testosterone, dihydrotestosterone, and estradiol in the plasma. Changes in its concentration significantly affect the ratio of unbound (biologically active) testosterone to estradiol in plasma.
(12 Dec 1998)
sex steroid-binding globulin A protein that transports 65% of the testosterone in plasma.
Synonym: sex steroid-binding globulin.
(05 Mar 2000)
single stranded binding protein <protein> SSB's are proteins responsiblefor holding the replication fork of DNAopen while polymerases readthe templates.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á